Surgically managed gastrointestinal stromal tumors: A comparative and prognostic analysis

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 52-59

  Hassan, Imran ^a   You, Y Nancy ^b   Shyyan, Roman ^b   Dozois, Eric J ^b   Smyrk, Thomas C ^b   Okuno, Scott H ^b   Schleck, Cathy D ^b   Hodge, David O ^b   Donohue, John H ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumor; Surgical resection; Target drug therapy; Tyrosine kinase inhibitor

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURGERY; COLON; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY BILLROTH I; GASTRECTOMY BILLROTH II; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ORGANIZATION; HUMAN; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; MITOSIS; PANCREATICODUODENECTOMY; PROCTOCOLECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECTUM; SEX RATIO; SMALL INTESTINE; STOMACH; STOMACH ANTRUM RESECTION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 38049173585     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9633-z     Document Type: Article

References (26)

1. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244:176-84
2. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127-34
3. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(Suppl 5):S83-7
4. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006;368(9544):1303-4
5. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329- 38
6. Dematteo RP, Antonescu CR, Chadaram Y, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II Trial ACOSOG Z9000 (abstract). Proc Am Soc Clin Oncol 2005:9009
7. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8
8. Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004;30:1098-103
9. Besana-Ciani I, Boni L, Dionigi G, et al. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 2003;92:195-9
10. Bumming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006;93:836-43
11. Miettinen M, El-Rifai W, HL Sobin L, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83
12. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9
13. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65
14. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005;103:821-9
15. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003;90:332-9
16. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-8
17. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9
18. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003;134:656-65
19. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-89
20. Ruka W, Rutkowski P, Nowecki Z, et al. Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monitor 2004;10:LE13-4
21. Chacon M, Roca E, Barugel M, et al. Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST). J Clin Oncol 2004;22(14 Suppl):9065
22. Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland 1990-2003: the Icelandic GIST Study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-93
23. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-7
24. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-42
25. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004;10:3282-90
26. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31